Beloranib

Overview

Beloranib (ZGN-440; CKD-732 free base) is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2 , thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β . Beloranib can be used in research on obesity and hypothalamic obesity.

Application

Products | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Obesity | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > MetAP | Products > Signaling Pathways > NF-κB

Product Information

• Catalog No.: HY-14811
• CAS No.: 251111-30-5
• Molecular Formula: C29H41NO6
• Molecular Weight: 499.64
• Purity: 89.63%
• Storage: -20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
• Availability: In-stock

Source

Original product source